Eli Lilly and Company $LLY Shares Sold by Golden State Wealth Management LLC

Golden State Wealth Management LLC trimmed its position in Eli Lilly and Company (NYSE:LLY) by 6.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 958 shares of the company’s stock after selling 61 shares during the quarter. Golden State Wealth Management LLC’s holdings in Eli Lilly and Company were worth $747,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. Brighton Jones LLC grew its position in shares of Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after purchasing an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after buying an additional 40 shares during the last quarter. Covestor Ltd lifted its holdings in shares of Eli Lilly and Company by 24.9% during the first quarter. Covestor Ltd now owns 426 shares of the company’s stock worth $352,000 after buying an additional 85 shares during the last quarter. Kaufman Rossin Wealth LLC bought a new stake in shares of Eli Lilly and Company in the first quarter valued at approximately $242,000. Finally, Opes Wealth Management LLC increased its position in Eli Lilly and Company by 6.6% during the first quarter. Opes Wealth Management LLC now owns 337 shares of the company’s stock worth $278,000 after acquiring an additional 21 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of research analyst reports. Leerink Partnrs lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. Guggenheim reaffirmed a “buy” rating and issued a $948.00 price target on shares of Eli Lilly and Company in a report on Thursday, October 16th. UBS Group decreased their price objective on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a report on Friday, August 8th. DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Finally, Berenberg Bank reiterated a “hold” rating and set a $830.00 price target (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $950.00.

Insider Buying and Selling

In other news, Director J Erik Fyrwald bought 1,565 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the purchase, the director owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO David A. Ricks purchased 1,632 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the transaction, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired 4,314 shares of company stock valued at $2,766,929 over the last 90 days. Company insiders own 0.14% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $938.13 on Friday. The company has a 50 day moving average of $796.15 and a 200-day moving average of $775.03. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $955.46. The firm has a market cap of $886.89 billion, a price-to-earnings ratio of 61.32, a PEG ratio of 1.21 and a beta of 0.43. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. During the same quarter in the prior year, the business earned $1.18 earnings per share. The business’s revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.